NasdaqGS:KNSABiotechs
Stronger Q2 Results And Higher 2026 Outlook Might Change The Case For Investing In Kiniksa (KNSA)
Kiniksa Pharmaceuticals International, plc has reported its second-quarter 2026 results, with revenue rising to US$243.6 million and net income reaching US$25.43 million, and has lifted its full‑year 2026 net product revenue guidance to a range of US$980 million to US$995 million from US$930 million to US$945 million.
This combination of stronger‑than‑prior earnings and an upgraded full‑year outlook, supported by ARCALYST growth and cardiovascular pipeline progress, signals improving...